BACKGROUND:3-(2,4-dimethoxybenzylidene)-anabaseine (DMXB-A) is a partial agonist at α7 nicotinic acetylcholine receptors that has been evaluated clinically for treatment of schizophrenia. This study examined the effects of DMXB-A on default network activity as a biomarker for drug effects on pathologic brain function associated with schizophrenia. METHODS:Placebo and two doses of DMXB-A were administered in a random, double-blind crossover design during a Phase 2 study of DMXB-A. Functional magnetic resonance imaging was performed on 16 nonsmoking patients with schizophrenia while they performed a simple eye movement task. Independent component analysis was used to identify the default network component. Default network changes were evaluated in the context of a polymorphism in CHRNA7, the α7-nicotinic acetylcholine receptor subunit gene, which was previously found to be associated with schizophrenia. RESULTS: Compared with placebo, both 150 and 75 mg twice daily DMXB-A altered default network activity, including a reduction in posterior cingulate, inferior parietal cortex, and medial frontal gyrus activity and an increase in precuneus activity. The most robust difference, posterior cingulate activity reduction, was affected by CHRNA7 genotype. CONCLUSIONS: The observed DMXB-A-related changes are consistent with improved default network function in schizophrenia. Pharmacogenetic analysis indicates mediation of the effect through the α7-nicotinic receptor. These results further implicate nicotinic cholinergic dysfunction in the disease and suggest that default network activity may be a useful indicator of biological effects of novel therapeutic agents.
RCT Entities:
BACKGROUND:3-(2,4-dimethoxybenzylidene)-anabaseine (DMXB-A) is a partial agonist at α7 nicotinic acetylcholine receptors that has been evaluated clinically for treatment of schizophrenia. This study examined the effects of DMXB-A on default network activity as a biomarker for drug effects on pathologic brain function associated with schizophrenia. METHODS: Placebo and two doses of DMXB-A were administered in a random, double-blind crossover design during a Phase 2 study of DMXB-A. Functional magnetic resonance imaging was performed on 16 nonsmoking patients with schizophrenia while they performed a simple eye movement task. Independent component analysis was used to identify the default network component. Default network changes were evaluated in the context of a polymorphism in CHRNA7, the α7-nicotinic acetylcholine receptor subunit gene, which was previously found to be associated with schizophrenia. RESULTS: Compared with placebo, both 150 and 75 mg twice daily DMXB-A altered default network activity, including a reduction in posterior cingulate, inferior parietal cortex, and medial frontal gyrus activity and an increase in precuneus activity. The most robust difference, posterior cingulate activity reduction, was affected by CHRNA7 genotype. CONCLUSIONS: The observed DMXB-A-related changes are consistent with improved default network function in schizophrenia. Pharmacogenetic analysis indicates mediation of the effect through the α7-nicotinic receptor. These results further implicate nicotinic cholinergic dysfunction in the disease and suggest that default network activity may be a useful indicator of biological effects of novel therapeutic agents.
Authors: R Freedman; H Coon; M Myles-Worsley; A Orr-Urtreger; A Olincy; A Davis; M Polymeropoulos; J Holik; J Hopkins; M Hoff; J Rosenthal; M C Waldo; F Reimherr; P Wender; J Yaw; D A Young; C R Breese; C Adams; D Patterson; L E Adler; L Kruglyak; S Leonard; W Byerley Journal: Proc Natl Acad Sci U S A Date: 1997-01-21 Impact factor: 11.205
Authors: Sherry Leonard; Judith Gault; Jan Hopkins; Judith Logel; Ruby Vianzon; Margaret Short; Carla Drebing; Ralph Berger; Diana Venn; Pinkhas Sirota; Gary Zerbe; Ann Olincy; Randal G Ross; Lawrence E Adler; Robert Freedman Journal: Arch Gen Psychiatry Date: 2002-12
Authors: William R Kem; Vladimir M Mahnir; Laszlo Prokai; Roger L Papke; Xuefang Cao; Susan LeFrancois; Kristin Wildeboer; Katalin Prokai-Tatrai; Julia Porter-Papke; Ferenc Soti Journal: Mol Pharmacol Date: 2004-01 Impact factor: 4.436
Authors: Jessica Finlay-Schultz; Andrew Canastar; Margaret Short; Mohamed El Gazzar; Christina Coughlan; Sherry Leonard Journal: J Biol Chem Date: 2011-10-06 Impact factor: 5.157
Authors: Jason Smucny; Korey P Wylie; Eugene Kronberg; Kristina T Legget; Jason R Tregellas Journal: J Psychiatr Res Date: 2017-02-03 Impact factor: 4.791
Authors: Manish S Dalwani; Jason R Tregellas; Jessica R Andrews-Hanna; Susan K Mikulich-Gilbertson; Kristen M Raymond; Marie T Banich; Thomas J Crowley; Joseph T Sakai Journal: Drug Alcohol Depend Date: 2013-10-24 Impact factor: 4.492
Authors: Randal G Ross; Sharon K Hunter; M Camille Hoffman; Lizbeth McCarthy; Betsey M Chambers; Amanda J Law; Sherry Leonard; Gary O Zerbe; Robert Freedman Journal: Am J Psychiatry Date: 2015-12-07 Impact factor: 18.112